EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2020-03-10 于是

问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？

149 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2020-01-22 阿卑罗王4c204ad1

外审了吗997384545_29380535 2020-01-20 发表::
审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表:
2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。

997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。

143 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2020-01-20 997384545_29380535

审稿速度:1.0
经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。

136 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2019-10-25 147612bem32暂无昵称

过万了吧

134 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2019-08-26 leook555

审稿速度:3.0 | 投稿命中率:25.0
经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。

129 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2019-07-10 有没有有没有有没有搞错

您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表:
老师.请教下EUR版面费多少.谢谢回复

土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复

113 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2019-03-02 12482f77m23暂无昵称

请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表:
临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。

fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。

135 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2019-02-20 chuttle

投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄

156 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2019-02-06 zhihenghuang

投了2个月，现在还在审稿中

146 0

[GetPortalCommentsPageByObjectIdResponse(id=586291, encodeId=1de1586291c7, content=问一下，这个杂志是只接收临床文章吗？如果也接收细胞动物实验文章，比例有多高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200622/4be1a0d65127407aa136d363c5d0c61b/f8be91f4ff5e4f82a160c4cfa55e044f.jpg, createdBy=e06a2151840, createdName=于是, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583757, encodeId=11b9583e5712, content=外审了吗997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。997384545_29380535 2020-01-20 16:03:00 发表: 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=997384545_29380535 2020-01-20 发表:: 审稿时间：约1个月 2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62481712256, createdName=阿卑罗王4c204ad1, createdTime=Wed Jan 22 00:00:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583661, encodeId=0e3258366120, content=审稿速度:1.0 经验分享：2019年12月23日投稿，2020年1月3日under review，1月6日拒稿，速度还算挺快的，还认真提了3条建议。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08e5231611, createdName=997384545_29380535, createdTime=Mon Jan 20 16:03:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578799, encodeId=a4425e87991c, content=过万了吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575373, encodeId=a8465e5373be, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：original article临床治疗方向，5月底投稿，第二天状态变成Under review，然后状态一直持续了2个月，中间写信催稿，主编说在审稿中，让再等等。8月17号突然收到拒稿，理由是审稿人未发回审稿意见。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2df1629638, createdName=leook555, createdTime=Mon Aug 26 16:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573533, encodeId=0a095e353349, content=您好，您知道版面费多少了吗？土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, beContent=土土zz 2018-05-13 00:00:00 发表: 老师.请教下EUR版面费多少.谢谢回复, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qh869sib5HsVhItqs1QibIxNLWWHSM5SuhsKIlz0EsDozicknEoaltbJYmibFTEhTegMQYxicfGUrtnUdicXndYibv5qA/132, createdBy=511e5126860, createdName=有没有有没有有没有搞错, createdTime=Wed Jul 10 00:00:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567522, encodeId=f48056e522c6, content=请问老师，文章被接收后还能修改作者吗？谢谢！fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, beContent=fzdndx 2018-12-09 00:00:00 发表: 临床肝病方向，投稿6次，秒拒3次，3次外审，不到一个月修回，而后顺利接收。总体上，难度不大，但对文章的创新性也有一点要求。语言要求不高。编辑还是很友好的，而且貌似愿意选择推荐的审稿人，哪怕推荐的是中国人。一般两个审稿人，有一次只有一个。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/01/d30c02f04ed4b1caee7add4b6a368a6d.jpg, createdBy=034c2493480, createdName=12482f77m23暂无昵称, createdTime=Sat Mar 02 00:00:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566977, encodeId=6d285669e73e, content=投了一篇，临床加实验，三天后回信说不适合杂志的范围。为了不耽误时间，给拒了。挺含蓄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=597b2378660, createdName=chuttle, createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566504, encodeId=b0c4566504fd, content=投了2个月，现在还在审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Wed Feb 06 08:25:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562039, encodeId=77e6562039b4, content=2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下： Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal. With kind regards Prof. Reinhold Stockbrugger Editor European Journal of Gastroenterology & Hepatology 请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。 继而改投Pancreatology，under review两月后被直接接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 16 09:57:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

2018-10-16 haifudao

2017年4月投过一篇胰腺癌的文章，被编辑秒拒，拒稿意见如下：
Thank you for submitting this paper to EJGH. I am not questioning the validity of your observations, or the methodology used, but I am very doubtful if your data would interest an international clinical audience, although colleagues in your own country might be interested. I feel therefore that a more suitable venue for this paper would be a national medical journal.

With kind regards

Prof. Reinhold Stockbrugger
Editor
European Journal of Gastroenterology & Hepatology
请了好几位同事看这个信，都觉得是编辑在歧视中国人，十分可恨。
继而改投Pancreatology，under review两月后被直接接受。

231 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务